• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Nektar Therapeutics (NKTR)

Common Shares
Sell: $82.03|Buy: $83.00|Change: 1.96 (2.41%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Address

455 Mission Bay Boulevard South
San Francisco
CA
USA
94158

Telephone

+1 415 4825300

Website

https://www.nektar.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Nektar Therapeutics Fourth Quarter Earnings Conference Call for 20262027-03-12T17:00:00
Nektar Therapeutics Fourth Quarter Earnings Results for 20262027-03-12T00:00:00
Nektar Therapeutics Annual Report for 20262027-03-12T00:00:00
Nektar Therapeutics Third Quarter Earnings Conference Call for 20262026-11-06T17:00:00
Nektar Therapeutics Third Quarter Earnings Results for 20262026-11-06T00:00:00
Nektar Therapeutics Second Quarter Earnings Conference Call for 20262026-08-07T17:00:00
Nektar Therapeutics Second Quarter Earnings Results for 20262026-08-07T00:00:00
Nektar Therapeutics Annual General Meeting for 20262026-05-22T14:00:00
Nektar Therapeutics First Quarter Earnings Conference Call for 20262026-05-08T17:00:00
Nektar Therapeutics First Quarter Earnings Results for 20262026-05-08T00:00:00

Previous key dates

NameKey Date
Nektar Therapeutics Annual Report for 20252026-03-13T00:00:00
Nektar Therapeutics Fourth Quarter Earnings Conference Call for 20252026-03-12T17:00:00
Nektar Therapeutics Fourth Quarter Earnings Result for 20252026-03-12T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-04T09:10:00
Nektar Therapeutics Analyst and Investor Event To Discuss REZOLVE-AA Topline Results2025-12-16T08:00:00
Jefferies Global Healthcare Conference2025-11-20T03:00:00
Nektar Therapeutics Third Quarter Earnings Conference Call for 20252025-11-06T17:00:00
Nektar Therapeutics Third Quarter Earnings Result for 20252025-11-06T00:00:00
Stifel 2025 Virtual Immunology and Inflammation Forum2025-09-15T14:30:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-10T10:30:00
Nektar Therapeutics Second Quarter Earnings Conference Call for 20252025-08-07T17:00:00
Nektar Therapeutics Second Quarter Earnings Results for 20252025-08-07T00:00:00
Nektar Therapeutics Annual General Meeting for 20252025-05-23T14:00:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference2025-05-20T13:30:00
Nektar Therapeutics First Quarter Earnings Conference Call for 20252025-05-08T17:00:00
Nektar Therapeutics First Quarter Earnings Result for 20252025-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.